Dennis Slamon

Specialty: Oncology (Breast Cancer)

Location: Los Angeles, United States

Tier: TITAN

H-Index: 130

Years Active: 0

Hospital Affiliations

• University of California, Los Angeles - Chief of Hematology-Oncology
• Jonsson Comprehensive Cancer Center - Director of Clinical and Translational Research

Techniques Invented

• HER2-targeted therapy with trastuzumab (Herceptin) [Gold Standard]

Key Publications

1. "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene" - Science (1987) [11702 citations]
2. "Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2" - New England Journal of Medicine (2001) [11460 citations]
3. "Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer" - Science (1989) [6845 citations]
4. "Palbociclib and Letrozole in Advanced Breast Cancer" - New England Journal of Medicine (2016) [2903 citations]
5. "Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease" - Journal of Clinical Oncology (1999) [2788 citations]
6. "Adjuvant Trastuzumab in HER2-Positive Breast Cancer" - New England Journal of Medicine (2011) [2756 citations]
7. "Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses" - Cell (2015) [1955 citations]
8. "The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study" - The Lancet Oncology (2014) [1899 citations]
9. "Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of <i>HER2</i>-Overexpressing Metastatic Breast Cancer" - Journal of Clinical Oncology (2002) [1854 citations]
10. "Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial" - The Lancet Oncology (2016) [1806 citations]

Knowledge Graph Relationships

Dennis Slamon is a Oncology specialist affiliated with University of California, Los Angeles, Jonsson Comprehensive Cancer Center. Invented techniques: HER2-targeted therapy with trastuzumab (Herceptin). Authored 10 scholarly articles.